What is Wedbush’s Forecast for ASND FY2029 Earnings?

Ascendis Pharma A/S (NASDAQ:ASND) – Wedbush lifted their FY2029 earnings per share estimates for shares of Ascendis Pharma A/S in a report released on Wednesday, February 12th. Wedbush analyst Y. Zhong now forecasts that the biotechnology company will earn $14.13 per share for the year, up from their previous estimate of $13.76. Wedbush currently has a “Outperform” rating and a $181.00 target price on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.12) per share.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.64.

A number of other research firms have also weighed in on ASND. The Goldman Sachs Group boosted their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday. JPMorgan Chase & Co. boosted their price objective on Ascendis Pharma A/S from $167.00 to $168.00 and gave the stock an “overweight” rating in a research report on Thursday. StockNews.com raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. TD Cowen cut their price target on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a report on Friday, November 15th. Finally, Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $193.43.

Ascendis Pharma A/S Stock Up 13.0 %

NASDAQ ASND opened at $142.49 on Friday. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $161.00. The company has a fifty day simple moving average of $132.19 and a 200 day simple moving average of $132.29.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock valued at $394,183,000 after purchasing an additional 753,859 shares in the last quarter. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S in the 3rd quarter valued at $60,000. Janus Henderson Group PLC grew its position in Ascendis Pharma A/S by 6.8% in the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after acquiring an additional 267,881 shares during the period. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after acquiring an additional 170,942 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Ascendis Pharma A/S by 9.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.